Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I

ROCKET PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$0.66

Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.
Cash and investments $330.3M as of March 31, 2024; expected operational runway into 2026.
EMA accepted MAA for RP-L102 (Fanconi Anemia); BLA submission to FDA expected H1 2024.
PDUFA date for KRESLADI (severe LAD-I) set for June 30, 2024; commercial preparations underway.
Appointed Aaron Ondrey as CFO and Meg Dodge as VP of Investor Relations & Corporate Communications.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKET PHARMACEUTICALS, INC. reported preliminary financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: preliminary results

Exact text from the filing

On May 6, 2024, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-024574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.